Privately-held, China-based biopharma company EpimAb Biotherapeutics has inked a deal with Spanish Dermatology company Almirall (BME: ALM).
EpimAb, a clinical stage company specializing in the development of multispecific antibodies, has agreed to out-license bispecific antibodies for up to three undisclosed target pairs.
Almirall will gain a license to use the firm’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to generate, develop and commercialize the candidates, for which it will gain exclusive global rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze